App-Quantinova.ai

The impact of changes to Joint British Diabetes Societies’ diabetes-related ketoacidosis management guidelines on trends of complications and outcome

Gobeka Ponniah - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hyperkalaemia

N/A

An audit of management of severe hyperlipidaemia in secondary and primary care services in greater london area

Bhavna Sharma - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic ketoacidosis

Mofezolac

Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models

Ismael da Conceiao - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Nonalcoholic fatty liver disease

Memantine

Somatostatin receptor splicing variant SST5TMD4 overexpression in glioblastoma is associated to poor survival, increased aggressiveness features and somatostatin analogs resistance

Jesus Perez Gomez - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic astrocytoma

Somatostatin

Circulating cell-free tumour DNA (ctDNA) utilisation in diagnosis and monitoring of thyroid cancer response to treatment - systematic review

Ali Al Jumaah - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Thyroid Cancer

N/A

Synergism between bisphenol a exposure and overweight/obesity in increasing the malignancy risk in a cohort of patients with thyroid nodules

Vincenzo Marotta - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Autoimmune Thyroid Disease

Bisphenol A

Are pre-operative intratumoral haemorrhages and post-operative bleeds sentinel indicators of ‘’silent’’ corticotroph adenomas?

Mohummad Shaan Goonoo - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Sexual brain processing is enhanced by melanocortin-4 receptor agonism

Layla Thurston - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

bremelanotide

Low post-operative cortisol after TSS for pituitary surgery predicts short term but not long term remission

Vanitha Karunakaran - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

European Registries for Rare Endocrine Conditions (EuRRECa): results from the core registry on hypothalamic and pituitary conditions

Ana Luisa Priego Zurita - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing’s disease: Results from the Phase III, prospective LINC 3 study

Rosario Pivonello - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Cushing's syndrome

DHEA-S

Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing’s disease treated with osilodrostat

John Newell-Price - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cushing's syndrome

LCI699

Independent injection vs healthcare-setting administration of somatostatin analogues: A systematic literature review

Cesar Luiz Boguszewski - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Severe Aortic Stenosis

Somatostatin

Cabergoline monotherapy in acromegaly – a multicenter, retrospective, cohort study of non-irradiated patients using current criteria for disease control

Sandrine A Urwyler - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acromegaly

Cabergoline

Is there a difference in clinical skills gained between healthcare professionals of high- and low and middle-income countries with online simulation-based learning?

Anisah Ali - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Aberrant expression of clock genes in human gastric neuroendocrine tumors type 1

Angeliki Karapanagioti - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Long-term Tolvaptan therapy in the treatment of SIAD in Elderly- A case report with challenging cytochrome P 450 drug interactions

Keerthi Madhurya Kethireddi - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Addison's disease

Demeclocycline

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

Maria Fleseriu - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acromegaly

octreotide long-acting release

Recovery of pituitary dysfunction following surgery and radiotherapy in non-functioning pituitary macroadenomas

Ziad Hussein - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pituitary adenomas

N/A

The screening and management of diabetes mellitus type 2 in patients with acromegaly- a tertiary centre service evaluation

Harry Gray - European Congress of Endocrinology (ECE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

hGH

Filters

45280 Abstracts